

DATE: \_\_\_\_\_ NEEDS BY DATE: \_\_\_\_\_ SHIP TO:  PATIENT  OFFICE - FIRST DOSE  OFFICE - ALL DOSES  OTHER \_\_\_\_\_

PATIENT INFORMATION		
Patient Name		
Address		
City	State	Zip
Main Phone	Alternative Phone	<input type="checkbox"/> Male <input type="checkbox"/> Female
Social Security #		Date of Birth

PRESCRIBER INFORMATION		
Prescriber Name		
Prescriber Type	<input type="checkbox"/> Physician (MD or DO)	<input type="checkbox"/> Nurse Practitioner <input type="checkbox"/> Physician's Assistant
Supervising Physician (If prescriber is a NP or PA)		
DEA #	NPI #	Tax ID #
Address		
City	State	Zip
Phone	Fax	
Contact Person		

CLINICAL INFORMATION			
Diagnosis: <input type="checkbox"/> M06.9 Rheumatoid Arthritis <input type="checkbox"/> H20.0 Iridocyclitis (Uveitis)	<input type="checkbox"/> L40.50 Psoriatic Arthritis <input type="checkbox"/> Other: _____	<input type="checkbox"/> M45.9 Ankylosing Spondylitis DX Code: _____	<input type="checkbox"/> M08.00 Juvenile Rheumatoid Arthritis
Patient Allergies:	Hepatitis Test Result:	Patient Weight:	Patient Height:
TB/PPD Test given? <input type="checkbox"/> Yes <input type="checkbox"/> No Test Date: _____	Test Results: _____		
Prior Failed Meds: <input type="checkbox"/> Actemra <input type="checkbox"/> Cosentyx <input type="checkbox"/> Cimzia <input type="checkbox"/> Enbrel <input type="checkbox"/> Humira <input type="checkbox"/> Kevzara <input type="checkbox"/> Orencia <input type="checkbox"/> Otezla			
<b>Methotrexate</b> Length of Treatment: _____	Reason for Discontinuing: _____		
_____ Length of Treatment: _____	Reason for Discontinuing: _____		
_____ Length of Treatment: _____	Reason for Discontinuing: _____		
Additional Information:			

**INSURANCE: PLEASE FAX BOTH SIDES OF PRESCRIPTION CARD AND MEDICAL CARD**

**LEFT BLANK**

**PATIENT INFORMATION**

Patient Name	Date of Birth	Prescription Date
--------------	---------------	-------------------

PRESCRIPTION INFORMATION			QUANTITY	REFILLS
<input type="checkbox"/> Olumiant	<input type="checkbox"/> 1 mg <input type="checkbox"/> 2 mg	Take 1 tablet by mouth daily	30	_____
<input type="checkbox"/> Orencia®	<input type="checkbox"/> 125mg PFS <input type="checkbox"/> 250mg Vials <input type="checkbox"/> 125mg Auto-Injector	<input type="checkbox"/> Inject 125mg SQ ONCE a week <input type="checkbox"/> Infuse _____ mg at _____	4 Week Supply	_____
<input type="checkbox"/> Otezla®	<input type="checkbox"/> Starter Pack <input type="checkbox"/> 30mg Tablets	<input type="checkbox"/> <b>Titrate:</b> Take 1 tablet on day 1 then twice daily as directed <input type="checkbox"/> <b>OR date provided</b> _____ <input type="checkbox"/> <b>Maintenance:</b> Take 1 tablet by mouth <b>ONCE</b> daily <input type="checkbox"/> <b>Maintenance:</b> Take 1 tablet by mouth <b>TWICE</b> daily.	1 Starter Pack 30 60	_____
<input type="checkbox"/> Otezla® <i>Bridge Rx</i>	30mg Tablets	<input type="checkbox"/> Bridge Rx: Take 1 tablet by mouth <b>TWICE</b> daily; dispensed by OSP <input type="checkbox"/> <b>(Recommended daily dose) ***Starter Pack Provided Date:</b> _____ <input type="checkbox"/> Bridge Rx: Take 1 tablet by mouth <b>ONCE</b> daily; dispensed by OSP <input type="checkbox"/> <b>(For Patients with severe renal impairment)</b>	28	_____
<input type="checkbox"/> Remicade®	100mg Vial	Infuse _____ mg at _____	_____	_____
<input type="checkbox"/> Rinvoq™	Please utilize manufacturer enrollment form and send to Avita			
<input type="checkbox"/> Simponi®	<input type="checkbox"/> 50mg SmartJect or <input type="checkbox"/> PFS <input type="checkbox"/> Aria	<input type="checkbox"/> Inject 50mg SQ ONCE a MONTH as directed <input type="checkbox"/> Infuse _____ mg at weeks 0 and 4, then every 8 weeks thereafter	4 Week Supply	_____
<input type="checkbox"/> Stelara®	<input type="checkbox"/> 45mg Prefilled Syringe <input type="checkbox"/> 90mg Prefilled Syringe <b>Weight Required:</b> _____	<input type="checkbox"/> Inject 45mg on day 0, then week 4, then every 12 weeks ( <b>Patients ≤ 220lbs</b> ) <input type="checkbox"/> Inject 90mg on day 0, then week 4, then every 12 weeks ( <b>Patients &gt; 220lbs</b> )	4 Week Supply	_____
<input type="checkbox"/> Taltz® <i>Psoriatic Arthritis Only</i>	<input type="checkbox"/> Auto Injector <input type="checkbox"/> Pre-filled Syringe	<input type="checkbox"/> <b>Initial:</b> Inject 160 mg SQ on week 0 <input type="checkbox"/> <b>Maintenance:</b> Inject 80 mg SQ every 4 weeks	2 1	_____
<input type="checkbox"/> Xeljanz®	<input type="checkbox"/> 5mg Tablets <input type="checkbox"/> 11mg XR Tablets	<input type="checkbox"/> Take 1 tablet by mouth <b>TWICE</b> daily <input type="checkbox"/> Take 1 tablet my mouth <b>ONCE</b> daily	60 30	_____
<input type="checkbox"/> Otrexup®			4 Week Supply	_____
<input type="checkbox"/> Rasuvo®			4 Week Supply	_____

Dispense As Written (no stamps)	Date	Substitution Permitted (no stamps)	Date
---------------------------------	------	------------------------------------	------

1. In order for a brand name product to be dispensed, the prescriber must write "Brand Necessary" or "Brand Medically Necessary" or any required state-specific language.  
 2. By signing this form, you are authorizing the pharmacy and its representatives to act on your behalf to obtain prior authorizations for the prescribed medication(s). We will also pursue available copy and financial assistance on behalf of your patients when available.  
 3. The pharmacy can only accept faxed prescriptions directly from a prescriber's office.  
 4. Prescribers must comply with any of their state-specific prescription requirements.